Cholangiocarcinoma — Trials

Cholangiocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

760 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 210
Recruiting: 120
Ph III recruiting: 7
Growth YoY: +17.4%
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (106)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07765433	Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer	not yet recruiting	Phase 2 / Phase 3	336	ECOG-ACRIN Cancer Research GroupNETWORK	0	Aug 14, 2026	clinicaltrials
NCT07691515	Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma(RAINBOW)	not yet recruiting	Phase 3	140	Zhejiang Cancer Hospital